Search results for "I h"

showing 10 items of 304 documents

METODI CHEMIOMETRICI NELLO STUDIO DEGLI INIBITORI DI HIV-1: TECNICHE STATITICHE MULTIVARIATE E MOLECULAR DOCKING

2006

METODI CHEMIOMETRICI INIBITORI DI HIV-1 TECNICHE STATITICHE MULTIVARIATE MOLECULAR DOCKINGSettore CHIM/08 - Chimica Farmaceutica
researchProduct

Anti-HIV Agents Derived from the ent-Kaurane Diterpenoid Linearol

2002

Twenty-six semisynthetic ent-kaurane derivatives of linearol (1) have been investigated for their anti-HIV effects. Five compounds (4, 7, 11, 25, and 26) showed significant activity against HIV replication in H9 lymphocyte cells with EC(50) values in the range <0.1-3.11 microg/mL. With TI values of 163 and 184, compounds 4 and 25 are especially promising for further development as potential anti-HIV agents.

Magnetic Resonance SpectroscopyAnti-HIV AgentsStereochemistryLymphocyteEnt kaurane diterpenoidHuman immunodeficiency virus (HIV)Pharmaceutical ScienceBiologymedicine.disease_causeAnalytical Chemistrychemistry.chemical_compoundDrug DiscoverymedicineCombinatorial Chemistry TechniquesHumansLymphocytesPharmacologyMolecular StructureAnti hivOrganic ChemistryHIVbiology.organism_classificationIn vitroTerpenoidmedicine.anatomical_structureComplementary and alternative medicinechemistryLentivirusSideritisMolecular MedicineDiterpenesDiterpeneJournal of Natural Products
researchProduct

Patterns of transmitted HIV drug resistance in Europe vary by risk group

2014

BACKGROUND: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. METHODS: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. RESULTS: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM…

MaleEpidemiologygenotypeHuman immunodeficiency virus 1HIV InfectionsRNA directed DNA polymerase inhibitorhigh risk patientLogistic regressionSettore MED/42 - Igiene Generale E ApplicataMen who have sex with men0302 clinical medicineImmunodeficiency Virusesmiddle agedstatistics and numerical data10. No inequalitySubstance Abuse Intravenous0303 health sciencesadulttransmissionvirus diseasesvirus transmissionhighly active antiretroviral therapyHIV immunopathogenesis3. Good healthMedical MicrobiologyViral Pathogenshigh risk behaviorMedicineScience & Technology - Other TopicsPOPULATIONShealth programanti human immunodeficiency virus agentUSERSmedicine.medical_specialtyScienceSexual BehaviorImmunologySexually Transmitted Diseasesintravenous drug abuse-Microbiology03 medical and health sciencesAntibiotic resistanceSDG 3 - Good Health and Well-beingHuman immunodeficiency virus infectionproteinase inhibitorHumansProtease InhibitorshumanHeterosexualityMicrobial PathogensseroconversionMedicine and health sciencesScience & TechnologyGenitourinary InfectionsMUTATIONSVirologymajor clinical studyLogistic Modelstransmitted drug resistance mutationHeterosexualityHIV-1Viral Diseases:Medical sciences: 700::Basic medical dental and veterinary sciences: 710::Medical immunology: 716 [VDP]drug responsemen who have sex with menDrug resistanceClinical immunologygeographyAPPEARANCEmale homosexualityMedizinische Fakultätimmune system diseasesEpidemiologyINFECTIONMedicine and Health Sciencessubstance abuse030212 general & internal medicineriskMultidisciplinaryACTIVE ANTIRETROVIRAL THERAPYTransmission (medicine)virus mutationQRarticleObstetrics and GynecologyHIV diagnosis and managementMiddle AgedvirologyMultidisciplinary SciencesEuropeInfectious Diseasesfemale:Medisinske fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716 [VDP]Reverse Transcriptase InhibitorsHIV clinical manifestationsFemaleepidemiologyblood samplingHIV drug resistanceResearch ArticleAdultRiskrisk-groupAnti-HIV AgentsUrologyprevalenceInfectious Disease Epidemiologysexual behaviorRisk-Takingmaleantiviral resistanceInternal medicineDrug Resistance Viralmedicinecontrolled studyddc:610Homosexuality Male030304 developmental biologydrug resistanceBiology and life sciencesbusiness.industrystatistical modelHIVCD4 lymphocyte countheterosexualitynonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionDiagnostic medicineINDIVIDUALSdrug effectsWomen's Healthbusinesstrend study
researchProduct

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

2016

Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.

MaleHuman immunodeficiency virus 1EtravirineRNA directed DNA polymerase inhibitordarunavirHIV InfectionsSettore MED/42 - Igiene Generale E Applicata:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Salud públicageneticsInhibidores de proteasas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]atazanavirmedia_commontransmission:Geographicals::Geographic Locations::Europe [Medical Subject Headings]3. Good healthmicrobial sensitivity testpriority journalEurope ; HIV-1 ; antiretroviral therapy ; drug resistance ; transmissionHIV/AIDSlamivudineReverse Transcriptase Inhibitors/pharmacologyanti human immunodeficiency virus agentDrugMicrobiology (medical)medicine.medical_specialtyantiviral susceptibility:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]media_common.quotation_subjectantiretroviral therapy030106 microbiologyHIV Infections/drug therapy:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors [Medical Subject Headings]Microbial Sensitivity TestsRILPIVIRINEArticleEFAVIRENZ03 medical and health sciencestransmitted drug resistanceSDG 3 - Good Health and Well-beingHumansTransmissionhuman:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance [Medical Subject Headings]REVERSE-TRANSCRIPTASE INHIBITORSRilpivirinaINTEGRASEMUTATIONSabacavirmajor clinical studyVirologyInfecciones por VIHRegimenAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Medicine (all); Microbiology (medical); Infectious DiseaseschemistryDrug resistance:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings]MutationHIV-10301 basic medicinenevirapineDrug resistanceCommunicable diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings]chemistry.chemical_compoundantiviral therapyINFECTIONMedicine and Health SciencesPrevalence:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]ViralNon-U.S. Gov'tReverse-transcriptase inhibitorantiretrovirus agentResearch Support Non-U.S. Gov'tMedicine (all)Human immunodeficiency virus infected patientMiddle AgedvirologyPREVALENCEAntiretroviral therapyEncuestas y CuestionariosANTIRETROVIRAL TREATMENTEuropeInfectious DiseasesHIV-1/drug effectsHIV Protease Inhibitors/pharmacologyRilpivirineReverse Transcriptase Inhibitors:Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings]FemaleHIV drug resistancemedicine.drugAdultHuman immunodeficiency virus proteinase inhibitor:Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings]EfavirenzAnti-HIV AgentsResearch SupportResistencia a medicamentosSettore MED/17 - MALATTIE INFETTIVEantiviral resistanceInternal medicineAnti-HIV Agents/pharmacologyDrug Resistance ViralJournal Articlemedicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors [Medical Subject Headings]abacavir plus lamivudineEuropa (Continente)Antiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Adult; Anti-HIV Agents; Drug Resistance Viral; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Microbiology (medical); Infectious DiseasesemtricitabinenonhumanIntervalos de confianzadrug resistanceMutaciónAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmissionbusiness.industryHIVpredictionInhibidores de la transcriptasa inversaHIV Protease InhibitorsHuman immunodeficiency virus 1 infectiontenofovirINDIVIDUALSDrug Resistance Viral/geneticsBenzoxazinasETRAVIRINEdrug effects3121 General medicine internal medicine and other clinical medicinePrevalenciabusiness
researchProduct

Low prevalence of anti-HCV antibody among Italian children

1994

The seroprevalence of anti-HCV antibody was studied among 2,749 children and teenagers (1,438 males and 1,311 females) living in Italy. Anti-HCV antibody testing was positive by both EIA and RIBA in ten (0.36%) subjects. The positivity rate increased with age, ranging from 0 among children less than 6 years of age to 0.8% among those aged 17-19 years chi 2 linear regression = 0.038). Anti-HCV prevalence ranged from 0.2% in northeastern regions and in Apulia to 0.6% in Sicily and Sardinia (p0.005), and no difference was seen between males (0.35%, C.I. 95%: 0.04-0.66) and females (0.38%, C.I. 95%: 0.04-0.66) (Fisher's exact test = 0.565). From these data it appears that in Italy HCV infection…

MaleMicrobiology (medical)Pediatricsmedicine.medical_specialtyAdolescentHepacivirusAnti hcv antibodyAge DistributionSeroepidemiologic StudiesPrevalenceHumansMedicineSeroprevalenceHepatitis AntibodiesSex DistributionChildbiologybusiness.industryGeneral MedicineHepatitis C AntibodiesExact testInfectious DiseasesItalyChild PreschoolPopulation SurveillanceLinear Modelsbiology.proteinFemaleAntibodybusinessDemographyInfection
researchProduct

Vaccine hesitancy and refusal among parents: An international ID-IRI survey

2022

Introduction: Although vaccines are the safest and most effective means to prevent and control infectious diseases, the increasing rate of vaccine hesitancy and refusal (VHR) has become a worldwide concern. We aimed to find opinions of parents on vaccinating their children and contribute to available literature in order to support the fight against vaccine refusal by investigating the reasons for VHR on a global scale.Methodology: In this international cross-sectional multicenter study conducted by the Infectious Diseases International Research Initiative (ID-IRI), a questionnaire consisting of 20 questions was used to determine parents' attitudes towards vaccination of their children.Resul…

MaleParentsHealth Knowledge Attitudes PracticeAn international ID-IRI survey- JOURNAL OF INFECTION IN DEVELOPING COUNTRIES cilt.16 sa.6 ss.1081-1088 2022 [Cag Y. Al Madadha M. E. ANKARALI H. ÇAĞ Y. Onder K. D. Seremet-Keskin A. Kizilates F. Civljak R. Shehata G. ALAY H. et al. -Vaccine hesitancy and refusal among parents]VaccinationGeneral MedicinePatient Acceptance of Health CareMicrobiologyCommunicable DiseasesparentInfectious DiseasesCross-Sectional StudiesVirologySurveys and Questionnairesvaccine refusalHumansvaccine refusal.ParasitologyFemaleVaccination HesitancyChildVaccine hesitancy
researchProduct

A qualitative study about immigrant workers’ perceptions of their working conditions in Spain

2009

Background: Spain has recently become an inward migration country. Little is known about the occupational health of immigrant workers. This study aimed to explore the perceptions that immigrant workers in Spain had of their working conditions. Methods: Qualitative, exploratory, descriptive study. Criterion sampling. Data collected between September 2006 and May 2007 through semi-structured focus groups and individual interviews, with a topic guide. One hundred and fifty-eight immigrant workers (90 men/68 women) from Colombia (n = 21), Morocco (n = 39), sub-Saharan Africa (n = 29), Romania (n = 44) and Ecuador (n = 25), who were authorised (documented) or unauthorised (undocumented) resident…

MaleQUALITAT RES METH FQImmigrants -- Salut i higieneEpidemiologyForeign workerImmigrationOccupational safety and health0302 clinical medicineUNESCO::CIENCIAS MÉDICAS ::Salud públicaImmigrants -- Condicions socials -- EspanyaMedicine030212 general & internal medicine10. No inequalitySocioeconomicsQualitative ResearchHealth inequalitiesmedia_commonSocial perceptionQualitative methodologyFocus GroupsMiddle Aged:CIENCIAS MÉDICAS [UNESCO]MIGRATION & HEALTH8. Economic growthUNESCO::CIENCIAS MÉDICASFemale0305 other medical scienceImmigrantAdultEmploymentmedicine.medical_specialtyAdolescentmedia_common.quotation_subjectEmigrants and ImmigrantsWorking conditionsWorkloadSampling StudiesOccupational medicine03 medical and health sciencesYoung AdultNursingqualitative ; inmigrant workers ; working conditionsHumans:CIENCIAS MÉDICAS ::Salud pública [UNESCO]inmigrant workers030505 public healthOccupational healthbusiness.industryPublic healthworking conditionsPublic Health Environmental and Occupational HealthHealth Status DisparitiesFocus groupSpainqualitativeImmigrants -- Treball -- EspanyaPerceptionWORKPLACEbusinessQualitative research
researchProduct

Demonstration of antibodies to the surface (anti-p41) and core proteins (anti-p24) of the human immunodeficiency virus (HIV) in individuals positive …

1987

Diagnosis of infection with the human immunodeficiency virus (HIV) relies on the demonstration of antibody to this virus. Occasionally, the combined analysis of sera using ELISA and western blot reveals false-positive results. We have compared a newly developed test to detect antibodies to the core (anti-p24) and surface (anti-p41) proteins of HIV with the established tests described above. Anti-p24 and anti-p41 were negative in three individuals positive for anti-HIV by ELISA and immunoblot; they had a low risk to acquire HIV infection and were clinically and immunologically normal and suspected false positive previously. In 62 individuals at risk, anti-p41 was always positive while anti-p…

MaleRiskRetroviridae Proteins OncogenicHuman immunodeficiency virus (HIV)Retroviridae ProteinsEnzyme-Linked Immunosorbent AssayHIV Antibodiesmedicine.disease_causeAntibodies ViralVirusAcquired immunodeficiency syndrome (AIDS)Western blotViral Envelope ProteinsAntibody SpecificityDrug DiscoverymedicineHumansGenetics (clinical)Acquired Immunodeficiency Syndromebiologymedicine.diagnostic_testAnti hivvirus diseasesHIVCore proteinGeneral Medicinemedicine.diseaseVirologyHIV Envelope Protein gp41Immunologybiology.proteinMolecular MedicineFemaleAntibodyKlinische Wochenschrift
researchProduct

Perdita di Massa ossea e severità della fibrosi epatica in una coorte di pazienti HIV/HCV co-infetti

2013

Massa ossea fibrosi epatica co-infetti HIV/HCV
researchProduct

Thermal stability and flammability of polyolefin/halloysite nanotubes composites

2015

Najnowsze badania w zakresie uniepalniania poliolefin są ukierunkowane na zastosowanie dodatku nanorurek haloizytowych (HNT) jako bezhalogenowego środka zmniejszającego palność, a jednocześnie zachowującego właściwości mechaniczne osnowy. Powstająca na powierzchni płonącego nanokompozytu, zawierającego HNT, warstwa tzw. zgorzeliny ogranicza przenikanie gazów oraz ciepła i zabezpiecza materiał przed dalszym paleniem. Unikatowa struktura HNT umożliwia dodatkowo pochłanianie produktów termicznego rozkładu poliolefinowej osnowy. Na podstawie dostępnej literatury dokonano oceny wpływu różnych czynników, m.in. modyfikacji nanorurek haloizytowych i/lub dodatku kompatybilizatora i/lub doboru odpowi…

Materials sciencePolymers and PlasticsGeneral Chemical Engineeringnanorurki haloizytowehalloysite nanotubesstabilnooeæ termicznaengineering.materialthermal stability and flame retardancyHalloysitePolyolefinpolyolefin nanocompositeschemistry.chemical_compoundchemistryMaterials ChemistryengineeringThermal stabilitynanokompozyty poliolefinoweComposite materialodpornooeæ ogniowaFlammabilityPolimery
researchProduct